187 related articles for article (PubMed ID: 38032827)
41. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
42. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial.
Paraiso MFR; Ferrando CA; Sokol ER; Rardin CR; Matthews CA; Karram MM; Iglesia CB
Menopause; 2020 Jan; 27(1):50-56. PubMed ID: 31574047
[TBL] [Abstract][Full Text] [Related]
43. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
44. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
45. Use of Growth Factors for Vulvo/Vaginal Bio-Stimulation.
Isaza PG
Surg Technol Int; 2019 May; 34():269-273. PubMed ID: 30388724
[TBL] [Abstract][Full Text] [Related]
46. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
Holton M; Thorne C; Goldstein AT
Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
[No Abstract] [Full Text] [Related]
47. What should guide our patient management of vulvovaginal atrophy?
Shapiro M
Climacteric; 2019 Feb; 22(1):38-43. PubMed ID: 30452294
[TBL] [Abstract][Full Text] [Related]
48. Modern approach to the management of genitourinary syndrome in women with gynecological malignancies.
Kovacevic N; Cilensek I; Merlo S; Segedin B
Radiol Oncol; 2023 Sep; 57(3):292-298. PubMed ID: 37494601
[TBL] [Abstract][Full Text] [Related]
49. Vulvovaginal atrophy in women after cancer.
Cox P; Panay N
Climacteric; 2019 Dec; 22(6):565-571. PubMed ID: 31411904
[TBL] [Abstract][Full Text] [Related]
50. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society.
Portman DJ; Gass ML;
Climacteric; 2014 Oct; 17(5):557-63. PubMed ID: 25153131
[TBL] [Abstract][Full Text] [Related]
51. [Genitourinary menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
Hocké C; Diaz M; Bernard V; Frantz S; Lambert M; Mathieu C; Grellety-Cherbero M
Gynecol Obstet Fertil Senol; 2021 May; 49(5):394-413. PubMed ID: 33757926
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
[TBL] [Abstract][Full Text] [Related]
53. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
Menopause; 2014 Oct; 21(10):1063-8. PubMed ID: 25160739
[TBL] [Abstract][Full Text] [Related]
54. New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review.
Benini V; Ruffolo AF; Casiraghi A; Degliuomini RS; Frigerio M; Braga A; Serati M; Torella M; Candiani M; Salvatore S
Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744033
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and tolerability of a plant-based, multi-component cream (Ginetrox®) in vulvovaginal disorders of the genitourinary syndrome during menopause.
Marrai R; Lissi G; Togni S; Maramaldi G; Barbara M; Giacomelli L
Minerva Ginecol; 2017 Jun; 69(3):245-249. PubMed ID: 28420227
[TBL] [Abstract][Full Text] [Related]
56. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
Simon JA; Ferenczy A; Black D; Castonguay A; Royer C; Marouf R; Beauchemin C
Menopause; 2023 Aug; 30(8):855-866. PubMed ID: 37369079
[TBL] [Abstract][Full Text] [Related]
57. Personal opinion: Treatment of vulvovaginal atrophy--are hidden interests and misinformation preventing better management?
Pines A; Sturdee DW
Climacteric; 2015; 18(6):802-4. PubMed ID: 26397968
[TBL] [Abstract][Full Text] [Related]
58. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
59. Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient?
Kearley-Shiers K; Holloway D; Janice Rymer ; Bruce D
Post Reprod Health; 2022 Dec; 28(4):237-243. PubMed ID: 36300276
[TBL] [Abstract][Full Text] [Related]
60. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
